Canceled by the investigator. Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)

Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029769

Enrollment

Unknown

Registered

2020-02-13

Start date

2020-02-15

Completion date

Unknown

Last updated

2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Experimental group:Routine treatment + Babaodan 6 capsules, bid orally

Control group:Conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Severe patients (according to any of the following): respiratory distress (RR> 30 beats / min); at rest, means oxygen saturation <= 93%; arterial oxygen pressure (PaO2) / oxygen concentration (FiO2) < = 300 mmHg

Exclusion criteria

Exclusion criteria: Children, pregnant women

Design outcomes

Primary

Measure	Time frame
28-day survival;Inflammatory factor levels;	—

Countries

China

Contacts

Public ContactLv Dongqing

Enze Hospital of Taizhou Enze Medical Center (Group)

lvdq@enzemed.com+86 13867622009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026